Pentosidine determination in CSF: A potential biomarker of Alzheimer's disease?

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 1, 2014, Pages 117-120

  Monacelli, Fiammetta ^a   Borghi, Roberta ^b   Pacini, Davide ^b   Serrati, Carlo ^b   Traverso, Nicola ^c   Odetti, Patrizio ^b  

^a Department of Internal Medicine and Medical Specialties ^*  (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Alzheimer dementia; cerebrospinal fluid (CSF); diagnosis; pentosidine

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PENTOSIDINE; TAU PROTEIN;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; NEUROFIBRILLARY TANGLE; NEUROTOXICITY; NITRATION; OLIGOMERIZATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; URINARY EXCRETION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ARGININE; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYSINE; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS;

EID: 84891453380     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0829     Document Type: Article

References (10)

1. Thorpe SR, Baynes JW. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9:69-77.
2. Finch CE, Cohen DM. Aging, metabolism, and Alzheimer disease: review, and hypotheses. Exp Neurol 1997;143:82-102.
3. Castellani RJ, Perry G, Harris PL, Monnier VM, Cohen ML, Smith MA. Advanced glycation modification of Rosenthal fibers in patients with Alexander disease. Neurosci Lett 1997;231:79-82.
4. Horie K, Myata T, Yasuda T, Takeda A, Yasuda Y, Maeda K, et al. Immunohistochemical localization of advanced glycation end products, pentosidine, and carboxymethyllysine in lipofuscin pigments of Alzheimer's disease and aged neurons. Biochem Biophys Res Commun 1997;236:327-32.
5. Serot J-M, Bene MC, Foliguet B, Faure GC. Morphological alterations of the choroid plexus in late-onset al.zheimer's disease. Acta Neuropathol (Berl) 2000;99:105-8.
6. Ahmed N, Ahmed U, Thornalley PJ, Hager K, Fleischer G, Münch G. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment. J Neurochem 2005;92: 255-63.
7. McKahnn G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
8. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992;4:153-9.
9. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, et al. Cerebrospinal fluid ?-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382-9.
10. Bar KJ, Franke S, Wenda B, Muller S, Kientsch-Engel R, Stein G. Pentosidine and N-?-(carboxymethyl)-lysine in Alzheimer's disease and vascular dementia. Neurobiol Aging 2003;24: 333-8.